Oncology · Clinical trials
Renal Cell Carcinoma Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About renal cell carcinoma — and why its trials are hard
Renal cell carcinoma (RCC), predominantly the clear-cell subtype, is characterized by VHL loss and consequent HIF-driven angiogenesis, making it uniquely responsive to VEGF-targeted therapy and, more recently, immune checkpoint blockade. The targeted era began with sunitinib in 2006, displacing cytokine therapy. The current standard for advanced disease is combination therapy: an immune checkpoint inhibitor paired with either a VEGF tyrosine kinase inhibitor or a second checkpoint agent. Pembrolizumab plus axitinib (KEYNOTE-426) and nivolumab plus cabozantinib (CheckMate-9ER) are widely used IO-TKI doublets, while nivolumab plus ipilimumab (CheckMate-214) offers durable responses in intermediate- and poor-risk patients. Cabozantinib remains a versatile single agent across lines. In 2023 belzutifan, a first-in-class HIF-2-alpha inhibitor, was approved for previously treated advanced RCC, introducing a mechanistically novel oral option and validating direct HIF targeting. Median survival for metastatic RCC now exceeds four years in favorable-risk patients, and IMDC risk stratification guides regimen selection.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Pembrolizumab + axitinib (Keytruda + Inlyta) | 2019 | First-line advanced RCC | KEYNOTE-426 (Phase III) | Overall survival and PFS vs sunitinib | OS HR 0.53 at first analysis; improved PFS and ORR across risk groups |
| Nivolumab + ipilimumab (Opdivo + Yervoy) | 2018 | First-line intermediate/poor-risk advanced RCC | CheckMate-214 (Phase III) | Overall survival vs sunitinib | OS HR 0.63 in intermediate/poor risk; durable complete responses ~9-11% |
| Nivolumab + cabozantinib (Opdivo + Cabometyx) | 2021 | First-line advanced RCC | CheckMate-9ER (Phase III) | PFS and overall survival vs sunitinib | PFS roughly doubled (median 16.6 vs 8.3 months); OS HR ~0.60 |
| Cabozantinib (Cabometyx) | 2016 | Advanced RCC after prior anti-angiogenic therapy | METEOR (Phase III) | PFS and overall survival vs everolimus | Median OS 21.4 vs 16.5 months; PFS HR 0.51 |
| Belzutifan (Welireg) | 2023 | Advanced RCC after PD-1/PD-L1 inhibitor and VEGF-TKI | LITESPARK-005 (Phase III) | PFS and ORR vs everolimus | Improved PFS and higher ORR (~22% vs 3.5%); first-in-class HIF-2-alpha inhibitor |
| Sunitinib (Sutent) | 2006 | First-line metastatic RCC (historical standard) | Pivotal Phase III vs interferon-alfa | Progression-free survival | Median PFS 11 vs 5 months; established VEGF-TKI era, long the control arm |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in renal cell carcinoma development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Atezolizumab + bevacizumab — IMmotion151 (Phase III) | Did not establish a definitive overall survival benefit | PFS improved in PD-L1-positive patients but OS was not statistically significant, and the regimen was superseded by IO-TKI doublets |
| Sunitinib (adjuvant) — ASSURE (Phase III) | Failed to improve disease-free survival after nephrectomy | No DFS or OS benefit with substantial toxicity; contrasted with the narrowly positive S-TRAC trial, leaving adjuvant TKI use controversial |
Choosing the right endpoint
Primary endpoints that matter in renal cell carcinoma trials
- Overall survival (OS) — The definitive endpoint; IO-TKI and IO-IO combinations earned first-line status largely on OS gains over sunitinib.
- Progression-free survival (PFS) — Primary in most targeted-therapy trials given RCC's angiogenesis dependence and reliable radiographic progression.
- Objective response rate (ORR) — Higher with combinations; complete-response rates matter for durability, especially with nivolumab plus ipilimumab.
- IMDC risk stratification — Not an endpoint per se but the key prognostic tool guiding regimen choice (favorable vs intermediate/poor risk).
- Disease-free survival (DFS) — The relevant endpoint in adjuvant trials post-nephrectomy; mostly negative except pembrolizumab (KEYNOTE-564).
How iNGENū runs renal cell carcinoma trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Renal Cell Carcinoma clinical trials — FAQs
What is the standard first-line treatment for metastatic clear-cell RCC?
What makes belzutifan different?
Is chemotherapy used in RCC?
Ready to discuss your renal cell carcinoma trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal